MetaCap

Capricor Therapeutics (CAPR) vs Evolus (EOLS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Capricor Therapeutics (CAPR) has outperformed Evolus (EOLS) over the past year, gaining 32.0% versus a loss of 4.8%. Over five years, CAPR leads with a +122.6% price change compared with +14.4% for EOLS. Capricor Therapeutics is the larger company by market cap ($441.3 million vs $431.5 million), about 1.0 times the size, while Evolus is growing revenue faster (+11.6% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAPR+32.00%EOLS-4.82%
+542%+236%-70%
Nov 21, 20251 yearNov 20, 2026
CAPR+127.93%EOLS+2.19%
+1009%+461%-87%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAPR versus EOLS key metrics
MetricCAPREOLS
Share price$7.59$6.52
Market cap$441.30M$431.55M
1-day change+0.80%-6.86%
YTD return-73.70%-1.95%
1-year return+32.00%-4.82%
5-year return+122.58%+14.39%
Forward P/E—22.68
EPS (TTM)$-2.65$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$297.18M
Revenue growth (YoY)-100.00%+11.61%
Net income (latest FY)$-105.04M$-51.64M
Gross margin—66.33%
Operating margin—-10.99%
Net margin—-17.38%
52-week high$40.37$9.31
52-week low$2.96$3.86
Distance from 52-week high-81.20%-29.97%
Analyst consensusbuystrong_buy
Avg. price target upside+259.03%+136.20%
Average volume4.73M925.77K
Shares outstanding58.14M66.19M
Employees231365
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CAPR has outperformed EOLS by 36.8 percentage points over the past year.
  • Evolus grew revenue faster in its latest fiscal year (+11.61% vs -100.00%).

About Capricor Therapeutics

CAPR stock →

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.

Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees

About Evolus

EOLS stock →

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.

Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees

CAPR vs EOLS FAQ

Which is bigger, Capricor Therapeutics or Evolus?

Capricor Therapeutics (CAPR) is larger, with a market capitalization of $441.30M compared with $431.55M for Evolus (EOLS).

Which stock has performed better over the past year, CAPR or EOLS?

CAPR returned +32.00% over the past 12 months, compared with -4.82% for EOLS (price return, excluding dividends). Past performance does not predict future results.

Are Capricor Therapeutics and Evolus in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons